anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A total of 50 patients will be enrolled in this double-blinded, randomized, controlled trial. Inclusion criteria: subjects\>40 yrs of age with an expected hospital stay in the Medical Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer (4 days bedridden) will be enrolled. Total drug treatment will be 6-14 days while in the hospital. A follow up phone call will be performed by the study team approximately 30 days after hospital discharge. Primary endpoint: bleeding rate (minor vs major) between study days 1-14. Secondary endpoint: DVT study days 1-14 (confirmed with LE duplex ultrasonogram).
Intimate partner violence (IPV) is a serious social and health issue. It is prevalent during pregnancy and in the postpartum period, causing tremendous effects on maternal and child health such as maternal depression, preterm birth, low birth weight, and impaired child neuropsychological development. However, IPV has been overlooked and is a low priority in China. No IPV intervention and prevention program has been implemented in China to help women deal with IPV in the perinatal period and eliminate its effects on maternal and child health. The Domestic Violence Enhanced Home Visitation Program (DOVE), which is a structured IPV intervention integrated into the perinatal home visitation program in the United States, focuses on educating and empowering women about IPV and their options for preventing further IPV. Building on the demonstrated effectiveness of the DOVE intervention in preventing IPV as well as the well-established perinatal care system in China, we adapted the DOVE intervention for the context of perinatal care in China. The aim of the proposed project is to test the feasibility and acceptability of the adapted DOVE intervention ("DOVE in China") in reducing maternal IPV and infant exposure to IPV and improving maternal and child health in a sample of women recruited from two perinatal clinics located in two cities (richer vs. poorer) of China. The pilot study will use a randomized two-arm pre-posttest control group design with repeated measures and mixed methods. A total of 25 women per group, who are in early pregnancy and screened positive for IPV in the year before pregnancy or during the current pregnancy, will be recruited at each of the two perinatal clinics. The intervention group will receive three prenatal sessions and one postpartum session, while the control group will receive standard of care. The frequency of IPV, depression, perceived stress, safety behaviors, birth outcomes, and child growth and development will be assessed on the web-based survey. The phone interview will ask about women's acceptability and satisfaction with the intervention and how it impacts their well-being. All women will complete the survey at baseline, 36-40 weeks before delivery, and 3 and 6 months postpartum. The interview will be conducted with women in the intervention group immediately post-intervention. The findings will help enhance the intervention by making appropriate modifications to the processes and procedures involved and provide a foundation upon which to implement a subsequent effectiveness trial. The findings will be disseminated through various means (e.g., publications, presentations). The long-term goal is to create an integrated, sustainable model for the universal screening, assessment, and treatment of IPV in China's perinatal care and improve the health of abused women and their infants.
The experimental group will be required to adhere to a diet consisting of a 12% reduction in calorie and a 1.2-1.5 g/kg body weight/day intake of protein. The participants will receive 6 times face-to-face meetings (on week 1, 2, 3, 4, 8 and 12) and weekly telephone call. Each face-to-face meetings will last for around 1 hour, during which the reseacher will help to establish the participants' intention for dietary behavior change, then help transform the intention into detailed plan, and help monitor the execution of the plan continuously.
206 patients with hepatocellular carcinoma(s) including up to three nodules measuring up to four cm in diameter, will be randomized in two therapeutic legs: multipolar no touch radiofrequency versus multipolar intra nodular radiofrequency. Patients previously treated for hepatocellular carcinoma will not be enrolled in the study. Diagnostic of hepatocellular carcinoma will be based on American Society of Liver Diseases guide line. Early response to the treatment will be assessed one month after the radiofrequency ablation procedures (up to three in case of incomplete necrosis) with dynamic contrast medium enhanced CT or MRI liver examinations. For the follow up dynamic contrast medium enhanced CT or MRI liver examinations will be performed every three months.

The trial will last for 73 months including 45 months for the recruitment of patients. The main criteria of judgement will be the 2-years recurrence rate.
In Part 2, subjects will receive non-RTV boosted GSK2838232 500 mg, given as single daily doses for 11 days. The dose will not exceed 500 mg (as 5 x 100 mg tablets) once daily (QD).
A pharmaceutical composition comprising proteins extracted from the New Zealand green-lipped mussel (Perna canaliculus) and one or more glycosaminoglycans, preferably glucosamine or glucosamine sulphate, has useful anti-inflammatory properties. This composition may be used in the treatment of arthritis conditions, such as osteoarthritis or rheumatoid arthritis. The combination of the protein extract and the glycosaminoglycan is synergistic with respect to the effect of the same concentration of the individual components of the combination. A preferred composition includes a homogeneous mixture of a freeze-dried powder containing proteins extracted from the mussel (about 66.6 wt%) and a glycosaminoglycan powder (about 33.3 wt%). A method for preparing this composition is described. The composition may be administered in capsule or tablet form.
Aim of the study was to assess of the impact of non-invasive ventilation with heliox on respiratory function, diaphragm bioelectrical activity, cerebral oxygenation and selected vital signs in premature neonates with respiratory failure. 23 neonates ≤32 weeks gestational age (GA) were enrolled in the study. Patients were eligible for inclusion when ventilated due to respiratory failure, and in group 1 (n=12) on NIV as primary modality with oxygen requirement of 0.25-0.4 in the first 72 hours of life, or in group 2 (n=11) ready to extubate according to the given criteria. Newborns were ventilated with NIV NAVA and standard breathing gas (air-oxygen) at baseline. Heliox was introduced for 3 hours, followed by 3 hours of air-oxygen. NAVA level was kept constant and pulse oximeter oxygen saturation (SpO2) kept in range of 90-95%. Recorded parameters included heart rate (HR), SpO2 and cerebral tissue oxygenation (StO2). Selected ventilation parameters: peak inspiratory pressure (PIP), positive end-expiratory pressure (PEEP), mean airway pressure (MAP), air leakage during NIV, fraction of inspired oxygen (FiO2) as well as electrical activity of the diaphragm (EaDI mean, minimum and maximum) were also acquired. Blood gas analysis was performed in each period of the study. Statistical analysis was completed with ANOVA Friedman's test and single-factor repeated-measures analysis of variance.
PURPOSE:To obtain a bathing agent having high tablet hardness and suppressing voluminal expansion of packaged article by tabletting powdery raw materials containing an oily component and flavors, etc., by using dextrin having a specific water content as a binder. CONSTITUTION:The objective bathing agent contains 0.5-50 pts.wt. inorganic salts, inorganic acids, organic acids, galenicals, coloring matters, vitamins, flavors, etc., usually used in bating agents and an oily component (e.g. natural oil and fat, beewax, vaseline or lauric acid). Furthermore, 0.1-60wt.% dextrin containing 1.0-6.0wt.% water content is mixed to the agent as a binder. The mixed powder is tabletted using a hydraulic tabletting machine and the resultant tablets are sealed by heat-sealing to afford the objective agent. Thereby, voluminal expansion of the packaged agent is suppressed even in such a case wherein an agent contains an acid and a carbonate in the powdery raw material.
Participants with advanced heart failure with a New York Heart Association class of III or IV symptoms within the last 3 months will be identified by either their outpatient heart failure clinic notes or inpatient cardiology notes. Patients will be approached for participation if cardiac rehab is mentioned in the notes and inclusion/exclusion criteria it met. Once the consent is signed, the baseline visit will be scheduled, this will be done before cardiac rehab has started. The baseline visit include frailty assessment measured by a walk time/gait speed test and handgrip strength test, and quality of life assessment measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and Minnesota Living with Heart Failure (MLHF) questionnaire. Patients will then attend cardiac rehabilitation for six week program. The cardiac rehab program will be designed by the individual facility due to the variation in exercise tolerance of each patient, no universal protocol will be used. After the six weeks of cardiac rehab, up to 16 weeks post-completion, the patient will return to Mayo Clinic Rochester to complete the frailty and quality of life assessment.
A computerized system for scheduling at least one daily activity of a user. One or more sensors are attached to the body of the user which monitor one or more physiological parameters of the body Physiological data is produced representative of the one or more physiological parameters during a time period. A processing unit attached to memory, is programmed for the scheduling of activities based on the physiological data and on previously stored values. The scheduled activities preferably include eating of a meal, exercise or rest of the user. Physiological parameters include skin temperature and/or heart rate. When the scheduled daily activity is eating of a meal, the processing unit is preferably programmed to recommend to the user to eat the meal during a portion of the time period when the skin temperature is rising or when the heart rate is falling.
The present invention relates to a weak alkaline carbazitaxel derivative and a formulation thereof, and specifically relates to the synthesis of the weak alkaline carbazitaxel derivative, a liposome formulation comprising the derivative, and use of the derivative in a drug delivery system, belonging to the technical field of medical technologies. The weak alkaline carbazitaxel derivative connects carbazitaxel to a weak alkaline intermediate by means of an ester bond, and the ester bond can be broken by means of the action of esterase in vivo, so as to release an active drug. The structural formula thereof is as follows: wherein a linker is a C 1 -C 4  alkyl, C 3 -C 6  cycloalkyl or phenyl; [N] is N-methylpiperazinyl, piperidinyl, 4-(l-piperidinyl)piperidinyl, morpholinyl, tetrahydropyrrolyl, or other tertiary amine structure. The weak alkaline cabazitaxel derivative can be used to prepare a liposome formulation. The liposome formulation has the characteristics of high drug loading, high encapsulation efficiency, and good stability. After the administration by injection, the liposome formulation can greatly improve the circulation time of the drug in vivo, increase the accumulation amount of the drug in the tumor site, and improve the anti-tumor effect and tolerance dosage.
Participation in the study will be offered to 10000 inhabitants of Bialystok aged 20-80 years. They will be randomly selected from the registry of Bialystok inhabitants. The goal of study is to discover novel risk factors and mechanisms underlying civilization diseases.
Prospective cohort of consecutive breast cancer patients requiring ribociclib for their standard of care at the clinically indicated dose, as per treating physician prescription (600mg to 200mg/day for 21 days per 28 days cycle). Association with other hormone-derived therapeutics will be allowed.
PROBLEM TO BE SOLVED: To obtain a hair growth agent capable of exhibiting remarkable hair growth effects and usable without anxiety by formulating an extract of seaweed in which the safety is proved in food uses, etc. SOLUTION: This hair growth agent is obtained by formulating an extract of Caulerpa lentillifera J. Agardoh. The extract of the Caulerpa lentillifera J. Agardoh is obtained by extraction-treating the Caulerpa lentillifera J. Agardoh with an organic solvent or water and can be obtained, by, e.g. dipping 100 g of a dried product of the Caulerpa lentillifera J. Agardoh in 1,000 ml of a 50% aqueous solution of ethanol, allowing the Caulerpa lentillifera J. Agardoh to stand for 10 days while occasionally stirring the mixture, filtering the mixture, then concentrating the filtrate under reduced pressure and freeze-drying the concentrate. The amount of the extract formulated with the hair growth agent is preferably 0.0001-15 wt.% expressed in terms of a dried substance.  Thereby, the readily available hair growth agent excellent in hair growth effects and usable without anxiety can be expected.
FIELD: medicine. SUBSTANCE: the preparation contains queen milk, extract of dry dog rose, extract of dry beet and additional substances necessary for obtaining a tableted form. The suggested preparation is of high therapeutical activity, nontoxic and convenient in application. It refers to curative- prophylactic preparations of plant origin to be used as an immunomodulator. EFFECT: higher efficiency. 1 cl, 3 tbl, 1 ex
Initial studies using Velcade in myelodysplasia with early results demonstrating that 35% had a partial response and 25% had stable disease. The combination of Velcade and thalidomide has been studied in patients with multiple myeloma, but not in patients with myelodysplasia. The CRR in the MM patients was 22%, with a good safety profile.

This is a phase 1, prospective, open-label, dose escalation study to evaluate the DLT and MTD of velcade with given in combination with thalidomide in patients with myelodysplasia. Treatment will be given as an outpatient. Patients will receive 4 days of Velcade (days 1, 4, 8, 11) and 21 days of thalidomide 50 mg/day for each 21 day cycle. There will be 3 cohorts of 3-6 patients each, plus 10 additional patients. The tree dose levels ill be 0.7, 1.0 and 1.3 mg/m2. Patients may continue to be treated up to 6 cycles. Cycles 2-6 will start within 2 weeks of completion of the previous cycle. Disease response will be evaluated after cycle 3 and 6.
Standard care over 52 weeks. Patients in the standard care group will use airway clearance techniques in the management of their BE.
BACKGROUND: The efficacy of balloon pulmonary angioplasty (BPA) in patients with chronic thromboembolic disease (CTEPD) without pulmonary hypertension (PH) remains unknown. Exercise PH (Ex-PH) is associated with impaired exercise capacity, even when pulmonary hemodynamics are normal at rest. We hypothesized that patients with Ex-PH could be the candidates for BPA. This study aimed to determine the prevalence and clinical profiles of Ex-PH and the effect of BPA on oxygenation and Ex-PH in patients with CTEPD and mean pulmonary arterial pressure (mPAP) ≤ 20 mmHg.
METHODS: We retrospectively reviewed 23 patients (median age 65 years) with CTEPD and mPAP ≤20 mmHg at rest who underwent cardiopulmonary exercise testing with right heart catheterization. Patients were divided into two groups: Ex-PH, defined by an mPAP/cardiac output (CO) slope (mPAP/CO slope) > 3.0, and non-Ex-PH.
RESULTS: Overall, 12 and 11 patients were identified as Ex-PH and non-Ex-PH groups, respectively. There were no significant differences in clinical parameters, including hemodynamics at rest, and blood gas analysis between Ex-PH and non-Ex-PH groups. Among 9 patients with Ex-PH, BPA improved World Health Organization-functional class and PaO2 at rest and was associated with a decrease in the mPAP/CO slope. All 3 patients discontinued LTOT after BPA. There were no significant complications during each BPA session.
CONCLUSIONS: Ex-PH was common among patients with CTEPD without PH. BPA could improve symptoms, oxygenation, and exercising hemodynamics in patients with CTEPD and Ex-PH.
BACKGROUND: Bronchiectasis is one of the most common comorbidities in severe asthma. However, the mechanisms by which asthma promotes the development and progress of this condition are not well defined. This study aimed to analyze the inflammatory phenotypes and quantify the expression of proinflammatory and remodeling cytokines in asthma patients with and without bronchiectasis.
METHODS: The study sample comprised individuals with severe asthma and bronchiectasis (group AB, n=55) and a control population of individuals with severe asthma without bronchiectasis (group AC, n=45). Induced sputum samples were obtained and cell types determined by differential cell count. Proinflammatory and bronchial remodeling cytokines (IL-8, neutrophilic elastase, TGFβ1, VEGF, IFN-γ, TNF-α, and GM-CSF) were analyzed by immunoassay in sputum supernatant.
RESULTS: Neutrophilic inflammation was the primary phenotype in both asthma groups. Higher levels of TGFβ1, VEGF and IFN-γ were observed in asthma patients with bronchiectasis (group AB) than in controls (group AC) (15 vs 24pg/ml, p=0.014; 183 vs 272pg/ml, p=0.048; 0.85 vs 19pg/ml, p<0.001, respectively). Granulocyte-macrophage colony-stimulating factor (GM-CSF) levels were significantly lower in the AB group than in the AC group (1.2 vs 4.4pg/ml, p<0.001). IL-8, neutrophil elastase and TNF-α did not present significant differences between the groups.
CONCLUSIONS: Raised levels of TGFβ1 and VEGF cytokines may indicate airway remodeling activation in asthma patients with bronchiectasis. The type of inflammation in asthma patients did not differ according to the presence or absence of bronchiectasis.
This an open-labeled study. All participants will be part of the treatment group and receive SAM-e. S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
A system operated over an electronic network for surveying nursing quality of nursing units at multiple healthcare facilities, comprises a first Web client connected to the network, a second Web client connected to the network, a database, a first Web server and a third Web client. The first Web client prompts at least one staff member of a first nursing unit of a first healthcare facility for a type of data relating to a nursing quality indicator, receives a first data element from the at least one staff member of the first nursing unit, and transmits a first unit type of the first nursing unit, a first identifier of the first healthcare facility, and the first data element. The second Web client prompts at least one staff member of a second nursing unit of a second healthcare facility for the type of data relating to the nursing quality indicator, receives a second data element from the at least one staff member of the second nursing unit, and transmits a second unit type of the first nursing unit, a second identifier of the second healthcare facility, and the second data element. The database stores the first data element along with the first unit type and the first identifier and stores the second data element along with the second unit type and the second identifier. The first Web server transmits the type of data relating to the nursing quality indicator to the first Web client and the second Web client, receives the first data element, the first unit type, and the first identifier from the first Web client, receives the second data element, the second unit type, and the second identifier from the second Web client, saves the first data element, the first unit type, the first identifier, the second data element, the second unit type, and the second identifier in the database, and if the first unit type and the second unit type are substantially the same type, performs a comparison of the first data element and the second data element stored in the database and organizes results of the comparison based on unit type and healthcare facility. The third Web client receives and displays the results from the first Web server, if the first unit type and the second unit type are substantially the same type.
OBJECTIVES: Thrombosis in antiphospholipid syndrome (APS) involves in most cases the venous circulation. Why in some patients thrombotic APS affects the arterial circulation and in particular cerebral circulation is unknown. In previous studies, both patient characteristics and antiphospholipid antibody types and titers have been associated with arterial thrombosis. Aim of this study was to compare the clinical characteristics and laboratory findings of venous and arterial thrombotic APS from a large series of patients.
METHODS: Data were retrieved from the Start 2 antiphospholipid, a multicenter prospective register of long-term collected data from Thrombosis Centers in Italy.
RESULTS: Of 167 patients with thrombotic APS, 114 (68 %) had a venous and 53 (32 %) had an arterial event as first clinical manifestation. Several clinical characteristics and risk factors were different among groups in univariate analysis. Using logistic regression analysis, reduced creatinine clearance and hyperlipidemia were independent variable for the occurrence of arterial APS. Notably, no difference in antiphospholipid antibody profiles and aβ2-Glycoprotein I levels were found between groups. A higher adjusted global antiphospholipid syndrome score (aGAPSS) was found in arterial group indicating a possible high recurrence rate in arterial APS.
CONCLUSIONS: These data have pathophysiological and clinical implication since associated conditions might predispose patients to arterial rather than venous events and call to a close monitoring and treatment of arterial APS due to their increased tendency to recurrence.
Patients receive a daily dose of ICV Valproate that increases from 3 mg to 60 mg (or MTD) over 8 weeks. A placebo week is randomly inserted in the dose escalation. During the placebo week, the patient receives normal saline.
The present invention is related with a Generator, Concentrator and electromagnetic fields (EMF) Router apparatus for cellular regeneration, especially for the regeneration or reactivation of cells affected by trauma, ulcers or wounds. The apparatus comprises an EMF Generator-Concentrator-Router (GCR-EMF) (15) which have a hollow container (1) of inverted truncated-cone shape, having a combination of horizontal coils (2), which are rolled around the container (1), and circular coils (3) and rectangular coils (4) that are located inclined on the walls of the hollow container. Rectangular and circular coils are intercalated equidistantly. This combination and location of coils allows the EMF to be produced and directed in three-dimensional space at the operator's discretion and as a function of time. What allows a greater accuracy when bordering the contour of the affected skin and excite the surface of the cell membranes. Excitation in this way entails an effective regeneration of cells of the cutaneous, muscular, nervous, and other tissues, decreasing and controlling the diabetic neuropathy and helping the cell growth to redo the skin tissues. Likewise, said EMF facilitate the destruction of biofilm (biofilm produced by bacteria), potentiating the effect of antibiotics. In patients requiring insulin, EMF decrease insulin resistance and improve the stabilization of the insulin effect, by minimizing high peaks (hyperglycemia) and low peaks (hypoglycemia).